

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**DIAGNOSTICS ASSESSMENT PROGRAMME**

**Equality impact assessment – Guidance development**

**Therapeutic monitoring of TNF inhibitors in Crohn’s  
disease (LISA-TRACKER ELISA kits, IDKmonitor  
ELISA kits, and Promonitor ELISA kits)**

**Consultation**

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

During scoping, pregnant women with Crohn’s disease receiving TNF inhibitor treatment were identified as a subgroup for whom therapeutic monitoring of TNF inhibitors may have added benefit over other patients with Crohn’s disease receiving TNF inhibitor treatment. However, clinical experts noted that the management of Crohn’s disease in pregnant women, including the use of therapeutic monitoring of TNF inhibitor, does not differ substantially from other people with Crohn’s disease, and that the clinical outcomes would not differ between pregnant women and others. It was decided that pregnant women do not need assessing as a subgroup, as the results of the assessment based on a general population would apply equally to pregnant women.

It was also noted that Crohn’s disease can have a substantial and long-term adverse effect on a person’s ability to carry out normal day-to-day activities. Therefore, people with Crohn’s disease may be covered under the disability provision of the Equality Act (2010).

2. Have any other potential equality issues been raised in the diagnostics assessment report, and, if so, how has the Committee addressed these?

No additional potential equality issues were raised during the assessment.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No other potential equality issues were identified by the Committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No

7. Have the Committee's considerations of equality issues been described in the diagnostics consultation document, and, if so, where?

No potential equality issues were identified.

**Approved by Programme Director (name):** Mirella Marlow

**Date:** 20 August 2015

## Diagnostics guidance document

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No additional potential equality issues were raised during consultation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

The recommendations did not change after consultation.

3. If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

The recommendations did not change after consultation.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

The recommendations did not change after consultation.

5. Have the Committee's considerations of equality issues been described in the diagnostics guidance document, and, if so, where?

No potential equality issues were identified.

**Approved by Centre or Programme Director:** Mirella Marlow

**Date:** 30/11/2015